Patents by Inventor Olaf Heidenreich

Olaf Heidenreich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi MODULATION OF MLL-AF4 AND USES THEREOF
    Publication number: 20120010267
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • RNAi modulation of MLL-AF4 and uses thereof
    Patent number: 8034793
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: October 11, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • DOUBLE-STRANDED RNA (dsRNA) AND METHOD OF USE FOR INHIBITING EXPRESSION OF A FUSION GENE
    Publication number: 20110065777
    Abstract: Specific inhibition of expression of a fusion gene in mammals occurs using a short, double-stranded ribonucleic acid molecule (dsRNA). The dsRNA comprises two separate non-linked RNA strands, an 51 strand and a complementary strand. The strands are 20 to 23 nucleotides in length, and the 51 strand is complementary to the fusion junction of the AML-1/MTG-8 fusion gene. The dsRNA also comprises at least 3 nucleotides on each side of the fusion junction. The dsRNA can be introduced into and maintained in a mammalian cell under conditions and for a time sufficient to obtain degradation of mRNA of the fusion gene to inhibit expression of the fusion gene. The dsRNAs and methods described are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Application
    Filed: October 26, 2010
    Publication date: March 17, 2011
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
    Patent number: 7846907
    Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • RNAi MODULATION OF MLL-AF4 AND USES THEREOF
    Publication number: 20100256218
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 7, 2010
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • RNAi modulation of MLL-AF4 and uses thereof
    Patent number: 7674779
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: March 9, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • RNAi MODULATION OF MLL-AF4 AND USES THEREOF
    Publication number: 20080233584
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: February 27, 2008
    Publication date: September 25, 2008
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • RNAi modulation of MLL-AF4 and uses thereof
    Patent number: 7361752
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: April 22, 2008
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
    Publication number: 20070185050
    Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Application
    Filed: January 22, 2007
    Publication date: August 9, 2007
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene
    Patent number: 7196184
    Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19–24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: March 27, 2007
    Assignee: Alnylam Europe AG
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • RNAi modulation of MLL-AF4 and uses thereof
    Publication number: 20060166918
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: December 14, 2005
    Publication date: July 27, 2006
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Modified ribozymes
    Patent number: 6890908
    Abstract: The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2?-position of the ribose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino and disubstituted amino groups, a process for the preparation of modified RNA molecules and the use of modified RNA molecules as therapeutic agents and biocatalysts.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: May 10, 2005
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heidenreich
  • Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
    Publication number: 20030190654
    Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Application
    Filed: January 22, 2003
    Publication date: October 9, 2003
    Applicant: Ribopharma
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • Modified ribozymes
    Patent number: 5672695
    Abstract: The claimed invention is drawn to RNA molecules with catalytic activity comprising at least one modified nucleoside having a modifier group replacing the hydroxy group at the 2'-position of the ribose sugar where the modifier group is an halo, amino, mono- or disubstituted amino, or an azido group.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: September 30, 1997
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heidenreich